Newswire (Published: Monday, December 11, 2017, Received: Thursday, December 7, 2017, 3:32:00 PM CST)
Word Count: 556
New Prostate Cancer Findings from Cleveland Clinic Outlined (The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a ...)
By a News Reporter-Staff News Editor at Clinical Trials Week -- Current study results on Oncology - Prostate Cancer have been published. According to news reporting from Cleveland, Ohio, by NewsRx journalists, research stated, "IsoPSA is a serum-based assay that predicts prostate cancer (PCa) risk by partitioning isoforms of prostate-specific antigen (PSA) with an aqueous two-phase reagent. To determine the diagnostic accuracy of IsoPSA in identifying the presence or absence of PCa and the presence of high-grade disease in a contemporary biopsy cohort."
The news correspondents obtained a quote from the research from Cleveland Clinic, "setting, and participants: Multicenter prospective study of 261 men scheduled for prostate biopsy at five academic and community centers in the USA enrolled between August 2015 and December 2016. Performance of the IsoPSA assay. Outcome measurements and statistical analysis: Discrimination power was evaluated using receiver operating characteristic (ROC) analysis. The outcome of the IsoPSA assay was transformed into risk probability using logistic regression. Decision curve analysis (DCA) was used to compare the net benefit of IsoPSA against other clinical protocols. Results and limitations: The overall prevalence was 53% for any PCa and 34% for high-grade PCa. The area under the ROC curve was 0.79 for any cancer versus none and 0.81 for high-grade PCa versus low-grade PCa/benign histology. In this preliminary study, DCA revealed a superior net benefit of IsoPSA against no biopsy, all biopsy, and the modified Prostate Cancer Prevention Trial Risk Calculator 2.0. At a cutoff selected to recommend biopsy, IsoPSA demonstrated a 48% reduction in false-positive biopsies; at a cutoff selected to identity men at low risk of high-grade disease, there was a 45% reduction in the false-positive rate. The structure-based IsoPSA assay outperformed concentration-based PSA measurement, and provided a net benefit against other protocols."
According to the news reporters, the research concluded: "Once validated, clinical use of IsoPSA could significantly reduce unnecessary biopsies while identifying patients needing treatment."
For more information on this research see: The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary. European Urology, 2017;72(6):942-949. European Urology can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; European Urology - www.journals.elsevier.com/european-urology/)
Our news journalists report that additional information may be obtained by contacting E.A. Klein, Cleveland Clinic, Glickman Urol & Kidney Inst, Dept. of Urol, Cleveland, OH 44106, United States. Additional authors for this research include A. Chait, J.M. Hafron, K.M. Kernen, K. Manickam, A.J. Stephenson, M. Wagner, H. Zhu, A. Kestranek, B. Zaslavsky and M. Stovsky (see also Oncology - Prostate Cancer).
Keywords for this news article include: Cleveland, Ohio, United States, North and Central America, Metastatic Prostate Cancer, Diagnostics and Screening, Prostate-Specific Antigen, Enzymes and Coenzymes, Risk and Prevention, Prostatic Neoplasms, Peptide Hydrolases, Cancer Prevention, Serine Proteases, Endopeptidases, Kallikreins, Oncology, Cleveland Clinic.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues
Medical Specialties and Practices
Medical and Pharmaceutical Regulation
Drug and Device Approval Process